US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,317.02

-6.6068-0.50%

Number of Gainers:- -

Number of Losers:3

Number of Flat:- -

PE:- -

High:1,332.36

Open:1,324.16

Low:1,311.24

Close:1,323.63

Loading ...

Gilead reports ASCENT-04/KEYNOTE-D19 study met primary endpoint

Gilead ASCENT-04 data a ‘welcome surprise,’ says Oppenheimer

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Gilead: Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study

THOMSON REUTERS

Gilead: Overall Survival (Os), Key Secondary Endpoint, Wasn't Mature at Time of Pfs Primary Analysis

THOMSON REUTERS

Gilead: Study Met Main Goal, With Statistically Significant,Clinically Meaningful Improvement in Pfs

THOMSON REUTERS

Gilead: Will Continue to Monitor Os Outcomes

THOMSON REUTERS

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated Pd-L1+ Metastatic Triple-Negative Breast Cancer

THOMSON REUTERS

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio

JOHNNIE WALKER ESTABLISHES A NEW STANDARD IN DESIGN INNOVATION BY INTRODUCING BLUE LABEL ULTRA, THE WORLD'S LIGHTEST WHISKY BOTTLE

Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell

MT Newswires Live

BRIEF-Nurix Announces FDA Clearance Of Ind Application For Gs-6791/Nx-0479

Nurix Therapeutics Inc - to Receive $5 Million Milestone Payment From Gilead

THOMSON REUTERS

Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know

Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid

MT Newswires Live

Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now?

Shares of bluebird bio Down 9% After Ayrmid Fails to Give Binding Offer

THOMSON REUTERS

BUZZ-Bluebird Bio falls after Ayrmid fails to give binding offer

bluebird bio Shares Down 7.9% at $4.12 Premarket After Ayrmid Fails to Give Binding Offer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4578/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1317.0244,"timestamp":1745263831940,"preClose":1323.6312,"halted":0,"volume":5499687,"delay":0,"changeRate":-0.004991,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-6.606812,"latestTime":"04-21 15:30:32 EDT","open":1324.1553,"high":1332.3552,"low":1311.2408,"amount":569693225.055773,"amplitude":0.015952,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745265600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.378866,"peRate":27.973188,"turnoverRate":0.001798,"increases":0,"decrements":3,"flats":0,"marketCap":347440928572,"floatMarketCap":328463007512},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1332.3552,"amplitude":0.015952,"preClose":1323.6312,"low":1311.2408,"pbRate":"5.378866","latestPrice":1317.0244,"volume":5499684,"delay":0,"open":1324.1553,"prevYearClose":1164.883,"prevWeekClose":1323.6312,"prevMonthClose":1364.0579,"prevQuarterClose":1364.0579,"fiveDayClose":1294.8855,"twentyDayClose":1344.9163,"sixtyDayClose":1188.045,"secType":"PLATE","market":"US","turnoverRate":0.001798,"peRate":27.973188,"marketCap":347440928572,"floatMarketCap":328463007512,"timestamp":1745263826389,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":0,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529800286","title":"Gilead reports ASCENT-04/KEYNOTE-D19 study met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2529800286","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529800286?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:15","pubTimestamp":1745244937,"startTime":"0","endTime":"0","summary":"Gilead Sciences (GILD) announced topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy plus Keytruda significan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-reports-ascent-04-keynote-d19-study-met-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-reports-ascent-04-keynote-d19-study-met-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0266013472.USD","LU0965509101.SGD","LU1917777945.USD","LU1035773651.USD","GILD","LU1116320901.HKD","LU0265550359.USD","BK4534","SG9999001176.USD","SG9999002232.USD","LU1941712348.USD","SG9999002224.SGD","LU0965509283.SGD","LU1983299246.USD","SG9999014575.USD","LU1023059063.AUD","LU1571399168.USD","BK4516","IE0002141913.USD","LU1116320737.USD","LU1585245621.USD","LU1989772840.SGD","LU1061106388.HKD","LU1093756325.SGD","SG9999001440.SGD","BK4568","LU0006306889.USD","BK4583","IE00B1BXHZ80.USD","LU0234572021.USD","LU1066051811.HKD","IE00BLSP4239.USD","LU0058720904.USD","LU2112291526.USD","LU1066051225.USD","IE00B2B36J28.USD","LU1430594728.SGD","LU2468319806.SGD","LU0109394709.USD","LU1934455277.USD","LU1941712264.USD","BK4585","BK4550","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","MRK","LU0861579265.USD","LU0289739699.SGD","LU2361044865.SGD","BK4578"],"gpt_icon":0},{"id":"2529800281","title":"Gilead ASCENT-04 data a ‘welcome surprise,’ says Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529800281","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529800281?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:15","pubTimestamp":1745244927,"startTime":"0","endTime":"0","summary":"Oppenheimer says Gilead (GILD) provided a “welcome surprise” this morning with ASCENT-04 hitting its primary endpoint. The firm was not expecting t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-ascent-04-data-a-welcome-surprise-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-ascent-04-data-a-welcome-surprise-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","GILD","BK4568","LU1066053197.SGD","LU1585245621.USD","IE00B19Z3581.USD","LU2468319806.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU1571399168.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","BK4139","IE00B3T34201.USD","LU0109394709.USD","BK4583","LU1066051498.USD","OPY","LU2087621335.USD","BK4532","BK4550","IE0002270589.USD","BK4588","LU0289739699.SGD","BK4566","BK4578","LU2089984988.USD","BK4585","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","BK4127","LU1839511570.USD"],"gpt_icon":0},{"id":"2529000618","title":"Why Investors Need to Take Advantage of These 2 Medical Stocks Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2529000618","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529000618?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:00","pubTimestamp":1745240408,"startTime":"0","endTime":"0","summary":"Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to look at a qualifying stock. CVS Health  holds a Zacks Rank #3 at the moment and its Most Accurate Estimate comes in at $1.68 a share 10 days away from its upcoming earnings release on May 1, 2025.CVS is one of just a large database of Medical stocks with positive ESPs. Another solid-looking stock is Gilead Sciences .This article originally publishe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-investors-advantage-2-medical-130008567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234570918.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","LU0061475181.USD","BK4581","GILD","LU0072461881.USD","BK4568","LU1066053197.SGD","LU0162691827.USD","LU1585245621.USD","ISBC","IE00B19Z3581.USD","LU0211331839.USD","LU2468319806.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU1571399168.USD","LU1699723380.USD","IE00B19Z3B42.SGD","BK4196","LU0320765992.SGD","BK4504","BK4139","IE00B3T34201.USD","LU0109394709.USD","BK4583","LU0006061336.USD","LU0070302665.USD","LU1066051498.USD","BK4211","LU2087621335.USD","BK4532","CVS","BK4550","LU0208291251.USD","IE0002270589.USD","LU1059921491.USD","BK4588","LU0289739699.SGD","BK4566","LU0320765489.SGD","BK4578","LU2089984988.USD","BK4585","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","LU1839511570.USD"],"gpt_icon":0},{"id":"2529805192","title":"Gilead: Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2529805192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529805192?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4585","LU0889565916.HKD","LU1839511570.USD","LU0320765992.SGD","GILD","LU0109394709.USD","BK4568","IE00B3T34201.USD","LU1430594728.SGD","LU1571399168.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0234570918.USD","BK4532","IE00BKVL7J92.USD","LU1066053197.SGD","LU2468319806.SGD","BK4578","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","IE00B19Z3581.USD","BK4550","LU2087621335.USD","LU2089984988.USD","BK4588","BK4139","LU1066051498.USD","LU1585245621.USD","BK4566"],"gpt_icon":0},{"id":"2529805167","title":"Gilead: Overall Survival (Os), Key Secondary Endpoint, Wasn't Mature at Time of Pfs Primary Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2529805167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529805167?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GILD","LU2089984988.USD","BK4568","BK4139","LU1571399168.USD","LU2468319806.SGD","IE00B19Z3581.USD","LU0058720904.USD","LU1839511570.USD","LU0109394709.USD","LU2087621335.USD","LU0289739699.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD","LU0889565916.HKD","LU1430594728.SGD","BK4588","BK4585","IE0002270589.USD","LU0320765992.SGD","LU0234570918.USD","IE00B3T34201.USD","LU1066053197.SGD","LU1585245621.USD","LU1066051498.USD","BK4583","BK4532","BK4550","BK4578"],"gpt_icon":0},{"id":"2529137805","title":"Gilead: Study Met Main Goal, With Statistically Significant,Clinically Meaningful Improvement in Pfs","url":"https://stock-news.laohu8.com/highlight/detail?id=2529137805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529137805?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GILD","IE00B3T34201.USD","IE00B7SZLL34.SGD","LU1571399168.USD","LU1839511570.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD","LU2089984988.USD","LU2468319806.SGD","LU0058720904.USD","BK4583","IE00BSNM7G36.USD","LU0289739699.SGD","BK4550","BK4139","IE00B19Z3B42.SGD","BK4585","BK4566","LU1066051498.USD","BK4578","IE00BKVL7J92.USD","LU0234570918.USD","BK4532","LU2087621335.USD","LU0889565916.HKD","LU1430594728.SGD","LU0109394709.USD","LU1585245621.USD","LU1066053197.SGD","BK4568","IE00B19Z3581.USD","IE0002270589.USD","BK4588"],"gpt_icon":0},{"id":"2529051968","title":"Gilead: Will Continue to Monitor Os Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2529051968","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529051968?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B19Z3581.USD","LU1571399168.USD","IE00BKVL7J92.USD","BK4585","LU1430594728.SGD","BK4568","LU0058720904.USD","BK4550","IE00B19Z3B42.SGD","LU1066053197.SGD","GILD","LU1066051498.USD","IE00BSNM7G36.USD","BK4532","LU0234570918.USD","LU1839511570.USD","IE00B3T34201.USD","BK4583","BK4566","LU2087621335.USD","LU1585245621.USD","IE0002270589.USD","LU0109394709.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4139","LU2089984988.USD","LU2468319806.SGD","IE00B7SZLL34.SGD","LU0289739699.SGD","BK4578","LU0889565916.HKD","BK4588"],"gpt_icon":0},{"id":"2529805156","title":"Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated Pd-L1+ Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529805156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529805156?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUACB5ZQM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1430594728.SGD","LU1585245621.USD","LU0889565916.HKD","LU0058720904.USD","BK4588","LU2087621335.USD","BK4532","BK4568","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU0234570918.USD","IE00B19Z3581.USD","LU0289739699.SGD","LU0109394709.USD","IE00BZ1G4Q59.USD","GILD","LU2089984988.USD","LU1571399168.USD","BK4585","LU1066053197.SGD","IE00B3T34201.USD","BK4566","IE0002270589.USD","LU1839511570.USD","IE00BKVL7J92.USD","BK4578","IE00B7SZLL34.SGD","BK4550","LU2468319806.SGD","LU0320765992.SGD","BK4139","BK4583","LU1066051498.USD"],"gpt_icon":0},{"id":"2529689806","title":"Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529689806","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529689806?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238600,"startTime":"0","endTime":"0","summary":"– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC –。– Trodelvy Plus Keytruda Shows an Early Trend in Improvement for Overall Survival Versus Standard of Care in Patients with Previously Untreated PD-L1+  mTNBC –。\"These findings are the first to show the transformative potential of an antibody-drug conjugate combined with an immuno-oncology agent in early treatment lines of metastatic breast cancer,\" said Dietmar Berger, MD, PhD, Chief Medical Officer, Gilead Sciences. \"For patients with this difficult to treat type of breast cancer, these results potentially offer a new pathway that may redefine their treatment options.\". The significant and meaningful improvement in PFS demonstrated in ASCENT-04 further reinforces the potential of Trodelvy plus Keytruda as a much-needed new treatment option for patients with previously untreated inoperable  PD-L1+ loca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trodelvy-plus-keytruda-demonstrates-statistically-123000256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SAR","LU1585245621.USD","IE00BKVL7J92.USD","LU0861579265.USD","IE00BJT1NW94.SGD","LU2087621335.USD","IE00BZ1G4Q59.USD","BK4585","LU0985320562.USD","LU0109394709.USD","LU1069347547.HKD","MCBS","ADC","LU2023250843.SGD","SG9999001176.USD","LU0106261372.USD","CINV","GILD","LU1162221912.USD","SG9999014542.SGD","PFS","ORR","BK4578","LU0965508806.USD","LU1023059063.AUD","LU0203347892.USD","IE00BSNM7G36.USD","BK4203","SG9999002232.USD","BK4007","LU2106854487.HKD","LU0208291251.USD","SG9999002224.SGD","LU1035773651.USD","HR","LU0965509283.SGD","IE00B1BXHZ80.USD","IE00BBT3K403.USD","LU0265550359.USD","LU1066051225.USD","LU2112291526.USD","LU2361045086.USD","LU1093756325.SGD","LU0234570918.USD","PD","MRK","OS","LU0203345920.USD","LU0234572021.USD","IE000M9KFDE8.USD"],"gpt_icon":0},{"id":"2528927170","title":"Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2528927170","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528927170?lang=en_us&edition=fundamental","pubTime":"2025-04-18 23:45","pubTimestamp":1744991109,"startTime":"0","endTime":"0","summary":"All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.Headquartered in Basel, Novartis  is a Medical stock that has seen a price change of 13.93% so far this year. The drugmaker is currently shelling out a dividend of $2.52 per share, with a dividend yield of 2.27%. This compares to the Large ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-novartis-nvs-top-dividend-154509467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002141913.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4588","BK4532","BK4578","IE00B2B36J28.USD","LU0211331839.USD","NVS","BK4007","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0070302665.USD","LU0208291251.USD","LU0320765489.SGD","BK4585","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2528069814","title":"JOHNNIE WALKER ESTABLISHES A NEW STANDARD IN DESIGN INNOVATION BY INTRODUCING BLUE LABEL ULTRA, THE WORLD'S LIGHTEST WHISKY BOTTLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2528069814","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528069814?lang=en_us&edition=fundamental","pubTime":"2025-04-18 20:00","pubTimestamp":1744977600,"startTime":"0","endTime":"0","summary":"Johnnie Walker Blue Label Ultra is the newest offering from the lauded whisky brand, continuing its legacy of innovation by creating the world's lightest 70cl Scotch whisky glass bottle. Culminating a five year journey, the patented glass used to create the bottle will be open-sourced and royalty-free for all. To celebrate the launch, Johnnie Walker is hosting an exhibition during NYCxDesign in May, showcasing new works and historic collaborations that define the beloved brand. With only 888 bottles available worldwide, this limited edition bottles feature select 'ghost whiskies' from now-closed distilleries. NEW YORK, April 18, 2025 /PRNewswire/ --Johnnie Walker, the world's number one Scotch whisky, unveils Blue Label Ultra, a limited edition first-of-its kind, boundary-breaking innovation. Weighing just 6.3oz , Johnnie Walker Blue Label Ultra is the world's lightest 70cl Scotch whisky glass bottle. Using new, patented glass technology developed by Diageo's design team this lighter, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/johnnie-walker-establishes-standard-design-120000414.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnnie-walker-establishes-standard-design-120000414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4578","BK4585","SMP","BK4556","DEO","BY","DGE.UK","BK4169","BK4559","BK4124","BLUE","BK4211","BK4588","BK4139"],"gpt_icon":0},{"id":"2528711090","title":"Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2528711090","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528711090?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:33","pubTimestamp":1744893215,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics  said Thursday that the US Food and Drug Administration has cleared an investigational new drug application for its oral IRAK4 degrader GS-6791/NX-0479, allowing for a phase 1 trial to start, which is expected to begin in Q2.The company said it is to receive $5 million from Gilead Sciences  for the IND clearance and remains eligible for up to $420 million in potential future milestone payments as part of a 2019 collaboration agreement.Nurix said GS-6791/NX-0479 has potential applications in rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis.Under the terms of the 2019 collaboration agreement, Nurix and Gilead Sciences  are looking to discover, develop, and commercialize a pipeline of up to five therapies for cancer and other diseases, the company said.Nurix shares were over 8% higher while Gilead shares were 0.2% higher in recent premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2087621335.USD","IE00B7SZLL34.SGD","LU0058720904.USD","LU2089984988.USD","BK4139","IE00B19Z3B42.SGD","BK4550","BK4588","43A.SI","IE00BZ1G4Q59.USD","BK4578","GILD","LU0320765992.SGD","LU1585245621.USD","BK4585","BK4568","BK4583","LU0234570918.USD","LU1066053197.SGD","LU1430594728.SGD","LU1066051498.USD","IE00BKVL7J92.USD","LU0109394709.USD","IE00B3T34201.USD","IE00BSNM7G36.USD","LU1839511570.USD","NRIX","BK6520","BK4532","BK4566","BK6054","LU0289739699.SGD","LU1571399168.USD","IE00B19Z3581.USD","LU2468319806.SGD","LU0889565916.HKD","IE0002270589.USD"],"gpt_icon":0},{"id":"2528790993","title":"BRIEF-Nurix Announces FDA Clearance Of Ind Application For Gs-6791/Nx-0479","url":"https://stock-news.laohu8.com/highlight/detail?id=2528790993","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528790993?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:04","pubTimestamp":1744887869,"startTime":"0","endTime":"0","summary":"BRIEF-Nurix Announces FDA Clearance Of Ind Application For Gs-6791/Nx-0479 April 17 (Reuters) - Nurix Therapeutics Inc NRIX.O:NURIX ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR GS-6791/NX-0479 - A N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA7XL3YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD","NRIX","LU1571399168.USD","LU1066051498.USD","LU2468319806.SGD","BK4566","LU1585245621.USD","BK4532","GILD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4550","IE00B19Z3581.USD","BK4585","BK4583","BK4139","BK4588","IE00BKVL7J92.USD","BK4578","LU0234570918.USD","BK4568","LU2089984988.USD","LU2087621335.USD","LU0109394709.USD","IE00B3T34201.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","LU1839511570.USD","LU1430594728.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2528797017","title":"Nurix Therapeutics Inc - to Receive $5 Million Milestone Payment From Gilead","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797017?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:00","pubTimestamp":1744887601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA7XL3YT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1066051498.USD","BK4532","IE00BKVL7J92.USD","LU1839511570.USD","LU1430594728.SGD","BK4585","LU1585245621.USD","LU0109394709.USD","LU2089984988.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","NRIX","BK4139","BK4588","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU2087621335.USD","BK4550","BK4578","IE0002270589.USD","LU0320765992.SGD","LU1066053197.SGD","BK4566","LU1571399168.USD","LU0234570918.USD","IE00BSNM7G36.USD","LU0289739699.SGD","BK4568","BK4583","GILD","LU0889565916.HKD","IE00B3T34201.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2528578599","title":"Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2528578599","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528578599?lang=en_us&edition=fundamental","pubTime":"2025-04-17 06:00","pubTimestamp":1744840815,"startTime":"0","endTime":"0","summary":"The most recent trading session ended with Gilead Sciences  standing at $104.90, reflecting a -0.74% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss of 2.24%. Meanwhile, the Dow experienced a drop of 1.73%, and the technology-dominated Nasdaq saw a decrease of 3.07%.Shares of the HIV and hepatitis C drugmaker have depreciated by 4.13% over the course of the past month, outperforming the Medical sector's loss of 7.47% and the S&P 500's loss of 4.17%.Market participants will be closely following the financial results of Gilead Sciences in its upcoming release. The company plans to announce its earnings on April 24, 2025. In that report, analysts expect Gilead Sciences to post earnings of $1.73 per share. This would mark year-over-year growth of 231.06%. At the same time, our most recent consensus estimate is projecting a revenue of $6.83 billion, reflecting a 2.18% rise from the equivalent quarter last year.The Zacks Industry Rank ga","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-stock-moves-220015275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234570918.USD","BK4139","IE00BSNM7G36.USD","LU0289739699.SGD","BK4568","LU1839511570.USD","LU1585245621.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4588","IE00B19Z3581.USD","LU0058720904.USD","IE00B7SZLL34.SGD","BK4550","IE00B3T34201.USD","BK4585","BK4566","LU0889565916.HKD","BK4532","BK4578","GILD","BK4583","LU1066051498.USD","LU0109394709.USD","LU1066053197.SGD","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU2087621335.USD","LU1571399168.USD","LU2468319806.SGD","IE00BKVL7J92.USD","LU0320765992.SGD","LU2089984988.USD"],"gpt_icon":0},{"id":"2527407812","title":"Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid","url":"https://stock-news.laohu8.com/highlight/detail?id=2527407812","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527407812?lang=en_us&edition=fundamental","pubTime":"2025-04-16 22:58","pubTimestamp":1744815503,"startTime":"0","endTime":"0","summary":"Bluebird Bio  said Wednesday its board reaffirmed its support for its planned acquisition by Carlyle  and SK Capital as Ayrmid has not sent a binding or fully financed offer after three weeks of engagement, including a timeline extension.Bluebird said Ayrmid's proposal remained \"highly conditional\" even after it engaged with Ayrmid on two occasions.The company said it has recommended that all stockholders tender by May 2 into the current agreement with Carlyle and SK Capital.Under the deal announced in February, Bluebird agreed to be acquired and taken private by funds managed by Carlyle and SK Capital for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.Shares of Bluebird were down more than 6% in recent trading Wednesday.Price: 4.19, Change: -0.28, Percent Change: -6.26","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4578","BK4556","IE00BGHQF748.EUR","BLUE","BK4135","IE00B3QW5Z07.USD","CG","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2527324143","title":"Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527324143","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527324143?lang=en_us&edition=fundamental","pubTime":"2025-04-16 21:54","pubTimestamp":1744811662,"startTime":"0","endTime":"0","summary":"We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a look at where Gilead Sciences Inc.  stands against other undervalued quality stocks to buy now.On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined ‘The Exchange’ on CNBC to discuss her thoughts on how good quality companies can ride out turbulence in the market. Just like Warren Buffett and Charlie Munger, Biel also suggests inaction as an investment principle and believes that holding high-quality companies can help investors deal with market volatility. She emphasized conviction in investing instead of impulsive decision-making. Biel also noted the general resilience of the US economy, which mainly comes from a robust jobs market as it fuels the consumer-driven economy. She also expressed unease over the limited tools available to address a potential recession that could come from high levels of deficit spending. She thinks inefficien","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-135422051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE0002270589.USD","IE00B64PRP62.GBP","BK4568","LU0889565916.HKD","LU1571399168.USD","LU1839511570.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BSNM7G36.USD","QID","SQQQ","BK4588","NVIW.SI","NQmain","IE00B19Z3581.USD","BK4112","IE00BKVL7J92.USD","USAW.SI","BK4139","BK4583","LU0058720904.USD","LU1066053197.SGD","QLD",".IXIC","BK4578","LU0320765992.SGD","LU0234570918.USD","NDAQ","TSYW.SI","LU2210150020.SGD","LU2468319806.SGD","LU2095319765.USD","BK4532","GILD","BK4550","LU1430594728.SGD","MNQmain","LU2210149790.SGD","USJW.SI","LU0109394709.USD","IE00B7SZLL34.SGD","PSQ","IE00B19Z3B42.SGD","LU1066051498.USD","TQQQ","LU0289739699.SGD","BK4566","IE00B3T34201.USD"],"gpt_icon":1},{"id":"2527248751","title":"Shares of bluebird bio Down 9% After Ayrmid Fails to Give Binding Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527248751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527248751?lang=en_us&edition=fundamental","pubTime":"2025-04-16 21:34","pubTimestamp":1744810457,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU125:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLUE","BK4556","BK4139","BK4578"],"gpt_icon":0},{"id":"2527214083","title":"BUZZ-Bluebird Bio falls after Ayrmid fails to give binding offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527214083","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527214083?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:54","pubTimestamp":1744808091,"startTime":"0","endTime":"0","summary":"BUZZ-Bluebird Bio falls after Ayrmid fails to give binding offer** Shares of gene therapy firm Bluebird Bio BLUE.O down 8.7% at $4.08 premarket ** BLUE says privately held UK company Ayrmid Ltd has not submitted binding proposal to acquire it and has not obtained necessary financing ** Co in March received non-binding offer from Ayrmid for up to $110.5 million ** BLUE adds it continues to be at significant risk of defaulting on its loan covenants** Co's board reaffirms its recommendation in support of transaction with Carlyle CG.O and SK Capital, while recommending all stockholders tender into current agreement by May 2** BLUE agreed to be taken private by Carlyle and SK Capital Partners at discount in February** As of last close, stock has fallen 46.4% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nL4N3QU0YI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4139","IE00B3QW5Z07.USD","BK4135","CG","IE00BGHQF748.EUR","BK4578","BLUE","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2527214233","title":"bluebird bio Shares Down 7.9% at $4.12 Premarket After Ayrmid Fails to Give Binding Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527214233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527214233?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:49","pubTimestamp":1744807746,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU1K4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","BK4578","BLUE"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}